LIM-0705 dosed separately and in combination with tacrolimus will be safe and well tolerated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
44
Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.
Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.
Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.
Nucleus Network CCS-Austin
Heidelberg, Victoria, Australia
Nucleus Network CCS-AMREP
Prahran, Victoria, Australia
Safety and tolerability of LIM-0705 with and without co-administered drug (tacrolimus).
Time frame: 14 days
Pharmacokinetics of LIM-0705 with and without combination of co-administered drug (tacrolimus).
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.